Monitor upcoming 13F filings to see if active managers join the buying trend; passive accumulation may support short-term price stability, but lack of active buyer participation limits upside conviction.
CRBU drugs
CRBU drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $1.84entry
- T+1 · 9mo ago −4.35%α −3.43% · $1.76
- T+5 · 8mo ago +7.07%α +8.27% · $1.97
- T+20 · 8mo ago −6.52%α +1.42% · $1.72
- T+60 · 6mo ago +17.39%α +8.06% · $2.16
How similar events traded
Executive Summary
Three major passive institutional investors, Morgan Stanley, Wells Fargo, and UBS, significantly increased their positions in Caribou Biosciences (CRBU) during Q4 2024, collectively doubling their holdings and adding $2.4M in net new value. This coordinated accumulation suggests growing institutional interest despite recent insider selling, though the buyers are all passive managers, indicating potential index-driven or rebalancing activity rather than active conviction.
Key Financial Metrics
Institutional Positions
Net institutional flow: $2.4M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | DOUBLED | +129.5% | $4.4M | $2.0M |
| Wells Fargo | DOUBLED | +112.8% | $146.0K | $62.0K |
| UBS | DOUBLED | +152% | $630.0K | $322.0K |
Key Facts
- Morgan Stanley increased holdings from 1.20M to 2.75M shares (+129.5%), valued at $2.3M → $4.4M (+$2.0M)
- Wells Fargo increased from 43.2K to 92.0K shares (+112.8%), valued at $85K → $146K (+$62K)
- UBS increased from 157.3K to 396.4K shares (+152.0%), valued at $308K → $630K (+$322K)
- No institutional selling observed in this quarter
- All buyers are classified as mega-passive institutions
Financial Impact
3 institutions accumulated $2.4M in net new positions, bringing total current holdings to $5.1M
Risk Factors
- All buying activity came from passive institutions, which may reflect index rebalancing rather than fundamental optimism
- Recent insider selling (5 transactions totaling $47K) contrasts with institutional buying, suggesting divergent views
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CRBU-2024-Q4 |
Track record
13 reports on CRBU
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +28.02% at T+20 after the Oct 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.4487 settles Dec 7
- Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 ▲ +28.02% +26.68% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 ▼ −61.27% −60.71% vs SPY
- Jun 11, 202622w ago 8-K Bullish 6/10 Entry $1.66 to $1.94 ▲ +16.87% +14.98% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $1.66 to $1.94 ▲ +16.87% +14.98% vs SPY
- Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 ▼ −0.54% −2.17% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 ▲ +1.41% −3.55% vs SPY
- Mar 5, 202636w ago 8-K Mixed 5/10 Entry $1.82 to $1.95 ▲ +7.14% +9.19% vs SPY
- Mar 5, 202636w ago Press Release Mixed 6/10 Entry $1.82 to $1.95 ▲ +7.14% +9.19% vs SPY
- Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Viewing Entry $1.84 to $1.72 ▼ −6.52% +1.42% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers